Covidien Ltd. on Thursday announced its fiscal net income report for the second quarter, stating that it plunged by 30%, due to increasing dollar rates and decrease of sales, although sales results of its generic version OxyContin pain-killer were surprisingly strong.
The report was also negative, as it contained charge from Tyco International Ltd. for $183 million in order to settle shareholders situation. The fiscal year medical reports are predicted to be decreased by 3%, while sales of Imaging Solutions are falling in the range of 6-9%.
Подписаться на:
Комментарии к сообщению (Atom)
Комментариев нет:
Отправить комментарий